Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
-
Adult
-
Adult
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Antirheumatic Agents
-
Arthritis, Rheumatoid
-
Arthritis, Rheumatoid
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Double-Blind Method
-
Drug Therapy, Combination
-
Drug Therapy, Combination
-
Female
-
Female
-
Humans
-
Humans
-
Injections, Subcutaneous
-
Injections, Subcutaneous
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Receptors, Interleukin-6
-
Receptors, Interleukin-6
-
Treatment Outcome
-
Treatment Outcome